FindTrial
Sign In

Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C

Impact of Serum Alpha-fetoprotein Levels on the Response to Direct Antiviral Therapy in Egyptian Patients With Chronic Hepatitis C

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03402165
Enrollment
1200
Registered
2018-01-18
Start date
2017-01-01
Completion date
2022-12-30
Last updated
2018-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C

Brief summary

Alpha-fetoprotein Levels on the Response to direct Antiviral Therapy in Patients with Chronic Hepatitis C

Detailed description

Impact of Serum Alpha-fetoprotein Levels on the Response to direct Antiviral Therapy in Egyptian Patients with Chronic Hepatitis C

Interventions

DRUGSofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir

Response to DAAD's and developing HCC

Sponsors

Sherief Abd-Elsalam
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* HCV patients who will undergo treatment by direct acting antiviral agents.

Exclusion criteria

* Patients with decompensated liver disease

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with sustained virologic response6 monthsThe total number of patients with SVR in each group

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, md
sheriefabdelsalam@yahoo.com00201095159522

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026